StimCardio Secures $30 Million Series A Financing to Innovate Atrial Fibrillation Wearable Technology

StimCardio's Major Financing Round

StimCardio, a company committed to developing non-invasive wearable therapeutics for atrial fibrillation (AF), has recently announced the closure of an oversubscribed $30 million Series A financing. This round was led by the family office of John Slump, Metis Medtech, and included participation from Catalyst Health Ventures and several strategic corporate investors. This substantial influx of capital will support the company as it prepares for pivotal trials involving its promising product, Rhyvive.

Understanding the Atrial Fibrillation Challenge

Atrial fibrillation is a significant health issue affecting approximately 59 million individuals globally, according to a study published in the Journal of the American College of Cardiology. This condition can lead to serious complications, including stroke, and often requires interventions like catheter ablation as a primary method of managing symptoms and reducing recurrence. Despite advancements in this method, recurrent AF affects about 30-40% of patients, indicating a pressing need for innovative solutions.

Rhyvive: A Game Changing Approach

StimCardio aims to redefine the management of AF with Rhyvive, its investigational wrist-worn therapeutic device. Designed to extend the treatment beyond hospital settings, Rhyvive utilizes a unique approach involving median nerve stimulation (MNS) to modulate pathways of the autonomic nervous system. This method aspires not only to reduce the recurrence of atrial arrhythmias but also to provide patients with a continuous therapeutic option in their own homes.

Amir Soltanianzadeh, the CEO of StimCardio, emphasized the company’s vision stating, “Our aim is to create a new therapeutic category in cardiac electrophysiology.” With this finance boost, StimCardio is committed to conducting a multi-center pivotal study that marks a significant stride into the realm of AF solutions targeting non-invasive therapies.

Backing from Industry Leaders

The enthusiasm from investors illustrates their confidence in StimCardio’s unique approach. John Slump, CEO of Metis MedTech, mentioned, “StimCardio is pioneering innovative technology positioned to disrupt the cardiac electrophysiology arena.” The ongoing challenges with AF recurrence signal an unmet clinical need, making StimCardio’s vision appealing to those seeking viable alternatives to existing treatments.

Pivotal Trial and Future Directions

Following StimCardio’s initial pilot study, NeuroPulse 1, presented at HRX Live 2026, the results showed a statistically significant reduction in recurrent AF events for those using active MNS compared to a sham group. The next phase, NeuroPulse 2, is set to evaluate the efficacy of combining wearable neuromodulation with catheter ablation, taking place across multiple centers to substantiate its claims further.

Conclusion

StimCardio's advancement in wearable technology for AF treatment not only reflects a timely response to a significant health concern but also positions the company at the forefront of a future where cardiac health monitoring may shift towards non-invasive options. As they move forward, the company intends to expand its research into additional cardiovascular applications, enhancing the landscape of cardiac treatment paradigms.

For continual updates, visit StimCardio’s official webpage or their LinkedIn profile as they progress on this transformative journey in healthcare.

About StimCardio: StimCardio Medical is innovating in the field of wearable neuromodulation therapeutics with a focus on addressing cardiac rhythm disorders. The vision includes broadening applications beyond atrial fibrillation to integrate further advancements in cardiovascular health management.